deltatrials
Completed PHASE3 NCT00778921

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone

A Randomized, Eight Week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (150/10 mg and 300/10 mg) in Comparison With Amlodipine 10 mg in Patients With Essential Hypertension Not Adequately Responsive to Amlodipine 10 mg Monotherapy

Sponsor: Novartis

Conditions Hypertension
Interventions Aliskiren 150 Amlodipine 10 mg Amlodipine 300
Updated 6 times since 2017 Last updated: Sep 20, 2016 Started: Oct 31, 2008 Primary completion: Jun 30, 2009 Completion: Jun 30, 2009

A PHASE3 clinical study on Hypertension, this trial is completed. The trial is conducted by Novartis and has accumulated 6 data snapshots since 2008. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Ankara, Turkey (Türkiye)
  • • Berlin, Germany
  • • Bratislava, Slovakia
  • • Buenos Aires, Argentina
  • • Oslo, Norway
  • • Stockholm, Sweden
  • • Warsaw, Poland